Acasti Pharma (NASDAQ:ACST) Shows Bullish Trend; Experts Expect Outstanding Figures For Its Stock

Acasti Pharma (NASDAQ:ACST) Shows Bullish Trend; Experts Expect Outstanding Figures For Its Stock

Acasti Pharma (NASDAQ:ACST) is showing a bullish trend, and experts believe that the ACST stock may come out with outstanding figures in the upcoming months in the market share. The performance of the ACST stock recently clearly indicated to the investors how they can expect better results in the latter months of 2020. The last trading showed ACST trading over 5.06M shares in volume, which is comparatively much more than its earlier trading session.

The opening stock value of ACST was $0.4892, which was high for that particular period. Later, the value of the stock came down by -3.41%, and then further, it touched a low of $0.433 closing that day at $0.46.It indicates that the price of the ACST stock went below by 0.44 as compared to its opening price.

Strong Momentum In Price Of ACST Stock

The recent strong momentum in the ACST stock value has triggered a positive opinion for the company’s stock, and analysts have already come out with their predictions. The analysts have estimated a price of $2.52 for the company’s stock within the consensus. They believe that this estimated price would ultimately set total gains of around 75.84% for the company, which is comparatively higher than the very recent closing price for ACST.

Currently, in the public float, the stock price is set at 81.82M, with market capitalization stable at $39.90M.

ACST Making Steady Progress With TRILOGY 1 Data

ACST is a biopharmaceutical innovator that has been involved in researching, developing, and commercializing its various prescription drug. Its exclusive drug candidate CaPre (omega-3 phospholipid), is being tested for treating severe hypertriglyceridemia (HTG). Recently the company came out with its business update, financial results, and operations for the 3rd quarter that ended on December 31, 2019.

The President and CEO of ACST, Jan D’Alvise, said, “We are making steady progress with the audit of TRILOGY 1 data and additional posthoc analyses. This data has been very informative, and provided we have the FDA’s support, any learnings we can take from this investigation that may allow us to adjust the Statistical Analysis Plan (SAP) for TRILOGY 2, gives us a better chance of accurately reflecting the clinical value that we see in CaPre. “

Published at Thu, 12 Mar 2020 14:36:27 +0000

Comments are closed.